Page 37

IS THIS NEW THERAPY READY FOR HUMAN TESTING? Clinical Trials: Testing the Promise When a new anticancer agent looks promising in preclinical testing, Fox Chase is perfectly positioned to confirm that promise in first-in-human (Phase 1) clinical trials. These critical early milestones are achieved with the help of the Developmental Therapeutics Program and the Phase I Early Drug Development Program (led by Anthony J. Olszanski, MD, RPh) through major collaborative efforts that bring together ABOVE Fox Chase researchers now lead

trials to find biomolecular signatures that will help select patients with head and neck cancer who can benefit from less intensive therapies. The urgency of such efforts to adjust treatment strategies based on the underlying cancer pathobiology and prognosis has been highlighted by the recent wave of oropharynx cancers related to HPV infection (shown here).

basic science researchers and physicians. These groups speed the translation of ideas between laboratory and clinic, while also ensuring the highest standards in IRB-approved study design, safety, and ethics. Today at Fox Chase, nearly 200 clinical trials are underway at any given time. Many of these trials are testing first-in-class agents or novel methods or tests. Early-phase clinical trials are a priority and a strength at Fox Chase—a fact recognized by the National Cancer Institute in its long-standing designation of the institution as a Comprehensive Cancer Center.

CANCER

33

Profile for Temple Health

Temple University School of Medicine - Highlights of Basic and Clinical Research - 2014  

Temple University School of Medicine is pushing the boundaries of science to help reduce the devastating effects of heart and lung disease,...

Temple University School of Medicine - Highlights of Basic and Clinical Research - 2014  

Temple University School of Medicine is pushing the boundaries of science to help reduce the devastating effects of heart and lung disease,...